Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest treatment options for this condition.

Medically reviewed by Stella Bard, MD Psoriatic arthritis (PsA) is a chronic (long-term) condition that includes symptoms of ...

Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

Visible signs of psoriatic arthritis appear months and even years before a person develops the full-blown inflammatory joint ...

Among a large cohort of young adults with psoriatic arthritis, 38.8% exhibited radiographic evidence of degenerative disc disease. Researchers in Canada conducted a retrospective cohort study to ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

Patients with psoriatic arthritis (PsA) experienced longer diagnostic delays than matched patients with rheumatoid arthritis (RA). Patients with polyarticular PsA received less intensive disease ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis. Findings from the Phase ...

Medically reviewed by Anita C. Chandrasekaran, MD Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that combines the skin-related symptoms of psoriasis with the joint-related symptoms ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...